KYORIN Pharmaceutical Co., Ltd. (TYO:4569)

Japan flag Japan · Delayed Price · Currency is JPY
1,660.00
-5.00 (-0.30%)
At close: Mar 6, 2026
0.12%
Market Cap 95.37B
Revenue (ttm) 133.26B
Net Income (ttm) 10.77B
Shares Out 57.45M
EPS (ttm) 187.40
PE Ratio 8.86
Forward PE 20.95
Dividend 52.00 (3.13%)
Ex-Dividend Date Mar 30, 2026
Volume 100,500
Average Volume 115,180
Open 1,651.00
Previous Close 1,665.00
Day's Range 1,639.00 - 1,662.00
52-Week Range 1,332.00 - 1,725.00
Beta -0.06
RSI 49.92
Earnings Date May 12, 2026

About KYORIN Pharmaceutical

KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, and Uritos KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis therapeutic agen... [Read more]

Sector Healthcare
Founded 1923
Employees 1,998
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4569
Full Company Profile

Financial Performance

In fiscal year 2025, KYORIN Pharmaceutical's revenue was 130.09 billion, an increase of 8.83% compared to the previous year's 119.53 billion. Earnings were 9.09 billion, an increase of 70.73%.

Financial Statements

News

There is no news available yet.